	US 11,998,518 B2
	Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
Mallory Factor, London (GB); and Michael Strupp, Munich (DE)
Assigned to INTRABIO LTD, Oxfordshire (GB)
Filed by INTRABIO LTD., Begbrook (GB)
Filed on Dec. 22, 2020, as Appl. No. 17/247,757.
Application 17/247,757 is a division of application No. 16/093,780, granted, now 10,905,670, previously published as PCT/GB2017/051090, filed on Apr. 19, 2017.
Claims priority of application No. 1606834 (GB), filed on Apr. 19, 2016.
Prior Publication US 2021/0106548 A1, Apr. 15, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/198 (2006.01); A61P 25/28 (2006.01)

CPC A61K 31/198 (2013.01) [A61P 25/28 (2018.01)]

11 Claims

1. A method of treating a decrease in cognitive function associated with ageing in a subject in need thereof comprising:

(a) identifying the subject having the decrease in cognitive function associated with ageing;

(b) taking a baseline measurement of the subject's cognitive function using one or more tests;

(c) administering a therapeutically effective amount of acetyl-leucine or a pharmaceutically acceptable salt thereof to the subject for a treatment duration;

(d) measuring the subject's cognitive function using the one or more tests after the subject is treated; and

(e) comparing the subject's cognitive function after treatment to the baseline measurement to determine if there is an improvement in the subject's cognitive function,

wherein the subject does not have vertigo or a neurological or neurodegenerative disease, disorder, or condition.